Use of Baricitinib in Patients with Moderate and Severe COVID-19

Link to article at PubMed

Titanji BK, et al. Clin Infect Dis 2020.


Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.

PMID:32597466 | DOI:10.1093/cid/ciaa879

Leave a Reply

Your email address will not be published. Required fields are marked *